Published in Blood Weekly, May 27th, 2004
According to recent research published in the journal Leukemia Research, "As fludarabine, topotecan and cytarabine (ara-C) are effective in AML, a pilot study of these three agents combined (FTA) was conducted."
"FTA consisted of topotecan 1.25 mg/m2 by CIV days 1-5, fludarabine 15 mg/m2 and ara-C 0.5 g/m2 IV, BID, on days 2-6," wrote F.J. Giles and colleagues, University of Texas M.D. Anderson Cancer Center.
"Seventeen patients (6 primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.